259 related articles for article (PubMed ID: 33629860)
61. Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model.
Qelliny MR; Aly UF; Elgarhy OH; Khaled KA
AAPS PharmSciTech; 2019 Jun; 20(6):237. PubMed ID: 31243601
[TBL] [Abstract][Full Text] [Related]
62. Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats.
Naserifar M; Hosseinzadeh H; Abnous K; Mohammadi M; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2020 Dec; 262():118555. PubMed ID: 33035579
[TBL] [Abstract][Full Text] [Related]
63. Research progress on berberine with a special focus on its oral bioavailability.
Liu CS; Zheng YR; Zhang YF; Long XY
Fitoterapia; 2016 Mar; 109():274-82. PubMed ID: 26851175
[TBL] [Abstract][Full Text] [Related]
64. Protective effects of panax notoginseng saponin on dextran sulfate sodium-induced colitis in rats through phosphoinositide-3-kinase protein kinase B signaling pathway inhibition.
Lu QG; Zeng L; Li XH; Liu Y; Du XF; Bai GM; Yan X
World J Gastroenterol; 2020 Mar; 26(11):1156-1171. PubMed ID: 32231420
[TBL] [Abstract][Full Text] [Related]
65. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
Zhao J; de Vera J; Narushima S; Beck EX; Palencia S; Shinkawa P; Kim KA; Liu Y; Levy MD; Berg DJ; Abo A; Funk WD
Gastroenterology; 2007 Apr; 132(4):1331-43. PubMed ID: 17408649
[TBL] [Abstract][Full Text] [Related]
66. Targeted delivery of NK007 to macrophages to treat colitis.
Chen S; Wang J; Cheng H; Guo W; Yu M; Zhao Q; Wu Z; Zhao L; Yin Z; Hong Z
J Pharm Sci; 2015 Jul; 104(7):2276-84. PubMed ID: 25964181
[TBL] [Abstract][Full Text] [Related]
67. Berberine represses Wnt/β-catenin pathway activation via modulating the microRNA-103a-3p/Bromodomain-containing protein 4 axis, thereby refraining pyroptosis and reducing the intestinal mucosal barrier defect induced via colitis.
Zhao X; Cui D; Yuan W; Chen C; Liu Q
Bioengineered; 2022 Mar; 13(3):7392-7409. PubMed ID: 35259053
[TBL] [Abstract][Full Text] [Related]
68. Combined ROS Responsive Polydopamine-Coated Berberine Nanoparticles Effective Against Ulcerative Colitis in Mouse Model.
Chang C; Liu H; Li X; Song D; Liu Y; Lu C; Zhen Y; Chen Y; Xu J; Li W; Jia X; Chen Z; Chen R
Int J Nanomedicine; 2024; 19():1205-1224. PubMed ID: 38348171
[TBL] [Abstract][Full Text] [Related]
69. A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis.
Chen H; Zhang F; Zhang J; Zhang X; Guo Y; Yao Q
Front Immunol; 2020; 11():588079. PubMed ID: 33072135
[TBL] [Abstract][Full Text] [Related]
70. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
[TBL] [Abstract][Full Text] [Related]
71. Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid.
Godugu C; Patel AR; Doddapaneni R; Somagoni J; Singh M
PLoS One; 2014; 9(3):e89919. PubMed ID: 24614362
[TBL] [Abstract][Full Text] [Related]
72. Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice.
Salaga M; Bartoszek A; Binienda A; Krajewska JB; Fabisiak A; Mosińska P; Dziedziczak K; Niewinna K; Talar M; Tarasiuk A; Kordek R; Fichna J
Nutrients; 2021 Aug; 13(8):. PubMed ID: 34444876
[TBL] [Abstract][Full Text] [Related]
73. Nanocarrier Based Delivery of Berberine: A Critical Review on Pharmaceutical and Preclinical Characteristics of the Bioactive.
Khan MJ; Hafeez A; Siddiqui MA
Curr Pharm Biotechnol; 2023; 24(11):1449-1464. PubMed ID: 36635907
[TBL] [Abstract][Full Text] [Related]
74. The in vivo fate of nanoparticles and nanoparticle-loaded microcapsules after oral administration in mice: Evaluation of their potential for colon-specific delivery.
Ma Y; Fuchs AV; Boase NR; Rolfe BE; Coombes AG; Thurecht KJ
Eur J Pharm Biopharm; 2015 Aug; 94():393-403. PubMed ID: 26117186
[TBL] [Abstract][Full Text] [Related]
75. In Vitro and In Vivo Evaluations of Berberine-Loaded Microparticles Filled In-House 3D Printed Hollow Capsular Device for Improved Oral Bioavailability.
Choudhury D; Jala A; Murty US; Borkar RM; Banerjee S
AAPS PharmSciTech; 2022 Mar; 23(4):89. PubMed ID: 35296955
[TBL] [Abstract][Full Text] [Related]
76. Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis.
Tambuwala MM; Manresa MC; Cummins EP; Aversa V; Coulter IS; Taylor CT
J Control Release; 2015 Nov; 217():221-7. PubMed ID: 26385165
[TBL] [Abstract][Full Text] [Related]
77. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
[TBL] [Abstract][Full Text] [Related]
78. Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation.
Kim W; Kim S; Ju S; Lee H; Jeong S; Yoo JW; Yoon IS; Jung Y
Mol Pharm; 2019 Sep; 16(9):4007-4016. PubMed ID: 31386809
[TBL] [Abstract][Full Text] [Related]
79. Dual-Targeted Nanoparticle-in-Microparticle System for Ulcerative Colitis Therapy.
Zhang Y; Wu Y; Yan Y; Ma Y; Tu L; Shao J; Tang X; Chen L; Liang G; Yin L
Adv Healthc Mater; 2023 Dec; 12(31):e2301518. PubMed ID: 37660262
[TBL] [Abstract][Full Text] [Related]
80. Maytenus robusta Reissek, a medicinal plant popularly used to treat digestive diseases, promotes ameliorative effects in colon and liver of mice exposed to dextran sulfate sodium.
Mees M; Meurer MC; Mariano LNB; Boeing T; Somensi LB; Mariott M; Niero R; Cechinel-Filho V; Andrade SF; Duarte LP; Sousa GF; de Souza P; Da Silva LM
J Ethnopharmacol; 2020 Oct; 261():113180. PubMed ID: 32730884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
